Cobimetinib

Advanced Sarcoma

OHSU Knight Cancer InstituteSmall moleculeEarly Phase 1Active

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 24/ 100
Competitive Position: 95/ 100

Competitive context

109 Active assets in the Advanced Sarcoma cohort.

Asset / Sponsor	Phase	Rating
ETOPOSIDE National Cancer Institute (NCI)	Phase 2	BB
Cyclophosphamide Essen Biotech	Phase 2	BB
Ifosfamide City of Hope Medical Center	Phase 3	BB
Inno-206 City of Hope Medical Center	Phase 3	BB
Carboplatin OHSU Knight Cancer Institute	Phase 2	BB

View all 50 →

Same molecule, other indications

Cobimetinib is also rated in:

malignant pancreatic neoplasmDormant

B

Indicative ·

62 / 100

melanomaDormant

B

Indicative ·

62 / 100

hematopoietic and lymphoid system neoplasmDormant

B

Indicative ·

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.